Oral psoriasis therapies: 54% PASI 100 and dosing differences
At week 48, 54% of patients in the open-label ONWARD3 extension achieved PASI 100 with envudeucitinib; three oral agents differ in dosing and responses at scalp, nail, palm and sole sites.